← Leaderboards
Robert K Boeckman
University Of Rochester
$1,118,694
Attributed
$1,529,190
Total exposure
4
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $372.7K · FY2015–17$500K$375K$250K$125K$0
'15
'16
'17
Funding mix
By agency
NIH$1,529,190 · 4
By mechanism
R01$784,948 · 2
R21$744,242 · 2
Top collaborators
- Lianping Xing3 shared
- Brendan F Boyce2 shared
Most similar at University Of Rochester
Same institution · by research overlap
- Jonathan W Friedberg$9,248,735
- Takahiro Takano$1,437,193
- Salvador Enrique Pena$116,737
- Edward M Schwarz$23,644,757
- Lianping Xing$7,584,078
Others in their field
Top investigators on “Tibia”
- Felix W Wehrli · University Of Pennsylvania$12,724,602
- Douglas P. Kiel · Hebrew Rehabilitation Center For Aged$10,435,348
- Steven M. Levy · University Of Iowa$9,132,650
- Steven R Cummings · University Of California San Francisco$7,628,506
- Ted S. Gross · University Of Washington$7,553,355
- Sundeep Khosla · Mayo Clinic Rochester$6,972,508
Research focus
TibiaAffectPreventTechnologyAdverse EffectsBone LossLabelPharmaceutical PreparationsDrug TargetingSiteIn VivoToxic EffectAnimal ModelIn VitroBoneChemistryBisphosphonateOsteoporosisAmericanDesignHypoglycemic AgentsAnalogBone ResorptionEnzyme-Linked Immunosorbent Assay
Grant awards (9)
Development of novel bone-targeted chloroquine conjugates to prevent bone resorption.$203,280
R21 · FY2017 · AR
Protein modification in bone cell regulation$169,400
R21 · FY2017 · AR
Protein modification in bone cell regulation$202,620
R21 · FY2016 · AR
Development of novel bone-targeted chloroquine conjugates to prevent bone resorption.$168,942
R21 · FY2016 · AR
Study of osteoblast regulation in TNF-mediated bone loss$76,750
R01 · FY2015 · AR
SYNTHESIS OF NOVEL BIOLOGICALLY ACTIVE NATURAL PRODUCTS$213,965
R01 · FY2002 · GM
SYNTHESIS OF NOVEL BIOLOGICALLY ACTIVE NATURAL PRODUCTS$243,838
R01 · FY2001 · GM
SYNTHESIS OF NOVEL BIOLOGICALLY ACTIVE NATURAL PRODUCTS$215,415
R01 · FY2000 · GM
SYNTHESIS OF NOVEL BIOLOGICALLY ACTIVE NATURAL PRODUCTS$34,980
R01 · FY2000 · GM